The Pennant Group (NASDAQ:PNTG) Delivers Strong Q2 CY2026 Numbers, Full

The Pennant Group (NASDAQ:PNTG) reported Q2 CY2026 revenue of $298 million, up 37.3% year over year, exceeding Wall Street estimates by 3.2%. Full-year revenue guidance was $1.18 billion at the midpoint, 1.3% above estimates. Non-GAAP EPS was $0.36, up from $0.27 and 9.1% above consensus.

Original reporting
Published Aug 5, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 9:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
The Pennant Group (NASDAQ:PNTG) Delivers Strong Q2 CY2026 Numbers, Full — source image
Decision brief

The 30-second read

$PNTGBullishMed
01

Why it matters

Q2 results and full-year revenue guidance modestly above consensus can re-rate near-term expectations, but the expected deceleration and stable margins temper the earnings-quality and valuation upside.

02

Market read

Traders can use the reported beats and guidance midpoint to reassess near-term estimates, while monitoring the implied deceleration in revenue growth.

03

What to watch

Adjusted operating margin is only 6.8% and in line with last year, while EPS growth is partly offset by share dilution, which may matter for per-share valuation.

Relevance 8/10Novelty 6/10Timing: after-hours/posted Aug 5, following Q2 CY2026 results and full-year guidance

Background

Pennant Group is a senior living provider operating home health, hospice, and senior living facilities across 13 western and midwestern states.

Company-level read

Ticker impact

$PNTGBullishMedium confidence
Context

Pennant Group beat Q2 CY2026 revenue expectations, with sales up 37.3% to $298M and full-year revenue guidance slightly above estimates.

Expected impact

Likely near-term support for the stock versus peers, with upside capped if investors focus on the guided deceleration.

Evidence & confidence

The text provides concrete beats (revenue, EPS) and a guidance midpoint that is only 1.3% above estimates, plus a stated deceleration in expected revenue growth and stable adjusted operating margin.

Market effects

Reinforces demand and pricing strength in senior living/home health, but margin stability suggests limited operating leverage upside.

No specific regional read-through beyond its footprint in western and midwestern states.

Limited, as it is a US-focused healthcare provider with no cross-border catalyst described.

Counterpoint

The guidance beat is small and the article highlights expected revenue growth deceleration, which can limit multiple expansion even after a strong quarter.

Key entities

  • The Pennant Group

    Senior living provider reporting Q2 CY2026 revenue and EPS beats and full-year revenue guidance.

  • Brent Guerisoli

    CEO quoted saying the company is on pace to exceed the top end of original full-year guidance.

Related articles

$PNTGMed

Pennant Group Inc (PNTG) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth

Pennant Group Inc (PNTG) discussed Q2 2026 earnings call topics including integration of Metasys assets in the Southeast, raised full-year guidance, and improved same-store margins. Management cited above-guided organic growth in home health and hospice, about $1.3 million Medicare hospice cap liability, and operating cash flow on track for up to $58 million. CFO said 2026 CapEx is $15-17 million tied to late-2025 distressed senior living acquisitions.

$PNTGHigh

Pennant Group, Inc. (PNTG): Results of Operations and Financial Condition

Pennant Group, Inc. (PNTG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningspressrelease.htm EX-99.1 Document Exhibit 99.1 Pennant Reports Second Quarter 2026 Results Conference Call and Webcast scheduled for tomorrow, August 6, 2026 at 10:00 am MT EAGLE, Idaho – August 5, 2026 (GLOBE NEWSWIRE) - The Pennant Group, Inc. (NASDAQ: P

$JANMedAI 8/10

JAN Q2 Earnings Call Highlights

Janus Living (NYSE:JAN) reported sequential same-store NOI margin down 40 bps, citing seasonality. Occupancy rose for independent living but fell for skilled nursing. The company acquired two communities for $105M, sold one for $23M, and completed $1B more acquisitions post-quarter. It raised 2026 FFO guidance to $0.95-$0.98 and same-store adjusted NOI growth to 13%-17%.

$JOBYMedAI 8/10

Joby Aviation Q2 Earnings Call Highlights

Joby Aviation (NYSE:JOBY) raised full-year revenue guidance to $115 million to $125 million from $105 million to $115 million. Q2 cash use was about $202 million and GAAP net loss was $245 million, including a $108 million non-cash warrant and earn-out fair value change. For 2H 2026, it expects $385 million to $415 million cash use. The company said aircraft availability is a key constraint on Blade routes and outlined manufacturing, infrastructure, and JV plans with Toyota.

$JHXMedAI 8/10

James Hardie Industries Q1 Earnings Call Highlights

James Hardie (NYSE:JHX) said about one-third of fiber-cement growth came from strategic initiatives, one-third from prior-year destocking comparisons, and the rest from price and mix. June sell-through rose 19%. Deck, Rail & Accessories sales fell 5% to $305.1M with 27.1% Adjusted EBITDA margin. Q2 net sales forecast $1.485B-$1.575B and FY2027 outlook raised; FCF Q1 was $254M and it redeemed $400M notes.

$IXMed

Orix Corp Ads Q1 Earnings Call Highlights

ORIX (NYSE: IX) discussed Q1 results and outlook on an earnings call, including potential Q3 Kioxia sale and valuation losses tied to Kioxia’s end-September share price. ORIX shifted its dividend basis to adjusted profits, targeting an interim dividend of JPY 107.27 per share and full-year JPY 187.36. It reported JPY 115.7B capital gains and about JPY 300B capital-recycling inflows, and continued a JPY 250B buyback.